Table 3.
Selected Studies of Autologous Stem Cell Transplantation in PCNSL
| Authors/ Study | N | Median Age (Range) |
Therapy Line | Therapy (Induction) | Reaction to Induction | Conditioning Regimen | WBRT | OS | Neurotoxicity |
|---|---|---|---|---|---|---|---|---|---|
| Abrey et al. [139] | 28 | 53 (25-71) |
First | HD-MTX- ARAC |
OR 50% CR 8/28 |
BEAM | No | 2 years 25% |
None |
| Illerhaus et al.(2006) [107] | 30 | 54 (27-64) |
First | HD-MTX- ARAC/TT |
OR 24/30 CR 10/30 |
BCNU/TT | Yes | 5 years 69% |
None |
| Illerhaus et al.(2008) [108] | 13 | 54 (38-67) |
First | HD-MTX- ARAC/TT |
OR 8/13 CR 4/13 |
BCNU/TT | Yes | 3 years 77% |
None |
| ∗Kasenda et al. [109] | 43 | First | HD-MTX- ARAC/TT |
BCNU/TT | Yes† | 5 years 82% |
None | ||
| Soussain et al. [112] | 43 | 52 (23-65) |
Salvage | CYVE | OR 20/43 CR 15/43 |
TT/BU/ ARAC | No | 2 years 45% |
None |
| Kiefer et al. [110] |
23 | 54 (18-69) |
First | HD-MTX | - | BU/ TT | Yes† | 10 years 35% |
10/23 |
| Schorb et al. [111] |
105 | 54 (23-70) |
First | HD-MTX based protocols | OR 84/105 CR 43/105 |
BCNU/TT or BEAM |
Yes† | 5 years 79% | None |
| Omuro et al. [94] | 32 | 57 (23-67) |
First | R-MPV | OR 31/32 CR 21/32 |
TT/BU/ ARAC | No | 2 years 81% | None |
PCNSL, primary central nervous system lymphoma; ARAC, cytarabine; BCNU, carmustine; BEAM, carmustine, etoposide, cytarabine, and melphalan; BU, busulfan; CYVE, cytarabine and etoposide; HD, high dose; MTX, methotrexate; OS, overall survival; R-MPV, rituximab, methotrexate, procarbazine, and vincristine; TT, thiotepa; WBRT, whole brain radiation therapy; -, not mentioned.
∗
This study was based on two studies above [Illerhaus et al. (2006) and Illerhaus et al. (2008)].
†
Only for patients not achieving a complete remission.